Get the Stockscreener App
0.6449
12.18%
0.07
After Hours:
.61
-0.0349
-5.41%
20 20 Biolabs Inc stock is traded at $0.6449, with a volume of 1.28M.
It is up +12.18% in the last 24 hours and down -51.87% over the past month.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
See More
Previous Close:
$0.5749
Open:
$0.5857
24h Volume:
1.28M
Relative Volume:
1.97
Market Cap:
$6.84M
Revenue:
$1.85M
Net Income/Loss:
$-5.56M
P/E Ratio:
-0.8505
EPS:
-0.7583
Net Cash Flow:
-
1W Performance:
-25.83%
1M Performance:
-51.87%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.5448
$0.68
1-Week Range:
$0.538
$0.989
52-Week Range:
$0.538
$14.09
20 20 Biolabs Inc Stock (AIDX) Company Profile
Name
20 20 Biolabs Inc
Sector
Industry
Phone
(240) 453-6339
Address
9430 KEY WEST AVENUE, ROCKVILLE
Compare AIDX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AIDX
20 20 Biolabs Inc
|
0.6449 | 6.32M | 1.85M | -5.56M | 0 | -0.7583 |
ABT
Abbott Laboratories
|
88.50 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.14 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.14 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.95 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.68 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
20 20 Biolabs Inc Stock (AIDX) Latest News
AIDX - Finviz
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
10 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Why Tower Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Trending Stocks Today | Aspire Biopharma up 6.03% Post-Market - Moomoo
AIDX Price Today: 20/20 Biolabs, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Get insights into the top gainers and losers of Friday's after-hours session. - ChartMill
20/20 Biolabs (AIDX) Surges 10.86%: Key Levels and Market SentimentETF AUM Growth - newsline.com
20/20 Biolabs (AIDX) Dips 7.75% – Key Support Test in FocusFactor Crowding - newsline.com
20/20 Biolabs (AIDX) Slumps 7.75% as Stock Nears Key $0.76 Support LevelFactor Rotation - newsline.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
20/20 Biolabs (NASDAQ: AIDX) asks shareholders to raise authorized shares to 500M - Stock Titan
20/20 Biolabs, Inc. Files Form 8-K Announcing Amended and Restated Bylaws and Nasdaq Listing as Emerging Growth Company - Minichart
20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters - The Manila Times
20/20 Biolabs' OneTest™ Selected for Vermont Firefighter Cancer Screening Initiative, Expected to Generate $500,000 in Revenue - Quiver Quantitative
20/20 Biolabs, Inc.Common Stock (Nasdaq:AIDX) Stock Quote - The Chronicle-Journal
20/20 Biolabs (NASDAQ: AIDX) cuts quorum for shareholder meetings - Stock Titan
No Analysis Provided - StocksToTrade
AIDX Slides As 20/20 Biolabs Inc. Faces Heavy Selling - timothysykes.com
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand - Sahm
Maxim Group Maintains 20/20 BIOLABS INC(AIDX.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
20/20 Biolabs: Buy Rating Reiterated on Growth Outlook and OneTest Momentum; $5 Price Target Maintained - TipRanks
AIDX Stock Slides As 20/20 Biolabs Tests Key Support - timothysykes.com
20/20 Biolabs stock surges on Ebola testing plans By Investing.com - Investing.com Australia
20/20 Biolabs stock surges on Ebola testing plans - Investing.com India
20/20 Biolabs Engages Pcr Test Kit Developers For Ebola And Hantavirus Testing - TradingView
20/20 Biolabs Commences Emergency Planning for Ebola & - GlobeNewswire
20/20 Biolabs 2Q Loss/Shr 28c >AIDX - Moomoo
20/20 Biolabs (NASDAQ: AIDX) registers 10.105M shares; posts Q1 2026 results - Stock Titan
McLean telehealth company seeks to raise $17.25M in IPO - The Business Journals
20/20 Biolabs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
20/20 Biolabs (AIDX) posts lower Q1 revenue and deeper loss after $5M preferred raise - Stock Titan
20/20 BioLabs reports Q1 2026 revenue $0.4M, net loss $2.17M, cash $4.2M - TradingView
Q1 2026: 20/20 BioLabs (AIDX) revenue declines as cash rises on $5M raise - Stock Titan
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress - The Manila Times
Press Release: 20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress - Moomoo
20/20 Biolabs, Inc. 1Q 2026: Revenue $353.38K, EPS ($0.28) — 10-Q Summary - TradingView
What Factors Led to 20/20 Biolabs' Dramatic Stock Collapse - Kavout
Maxim Group Initiates 20/20 BIOLABS INC(AIDX.US) With Buy Rating, Announces Target Price $5 - 富途牛牛
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
20/20 Biolabs (AIDX) delays 10-Q filing; expects 5-day extension - Stock Titan
AIDX SEC Filings20/20 Biolabs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Number of shareholders of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026 - GlobeNewswire
AIDX | 20/20 Biolabs, Inc. Common FinancialsIncome Statement - Quiver Quantitative
USC inks licensing agreement for prostate cancer screening tool - University of South Carolina
20/20 BioLabs Licenses Patented Algorithm from University of South Carolina for Early Detection of Aggressive Prostate Tumors - Quiver Quantitative
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina - The Manila Times
New PSA algorithm uses repeat blood tests to flag high-risk prostate tumors early - Stock Titan
20 20 Biolabs Inc Stock (AIDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):